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Abstract
Necroptosis is a regulated form of necrotic cell death that has been implicated in the pathogenesis of various diseases
including intestinal inflammation and systemic inflammatory response syndrome (SIRS). In this work, we investigated the
signaling mechanisms controlled by the necroptosis mediator receptor interacting protein-1 (RIP1) kinase. We show that Akt
kinase activity is critical for necroptosis in L929 cells and plays a key role in TNFa production. During necroptosis, Akt is
activated in a RIP1 dependent fashion through its phosphorylation on Thr308. In L929 cells, this activation requires
independent signaling inputs from both growth factors and RIP1. Akt controls necroptosis through downstream targeting
of mammalian Target of Rapamycin complex 1 (mTORC1). Akt activity, mediated in part through mTORC1, links RIP1 to JNK
activation and autocrine production of TNFa. In other cell types, such as mouse lung fibroblasts and macrophages, Akt
exhibited control over necroptosis-associated TNFa production without contributing to cell death. Overall, our results
provide new insights into the mechanism of necroptosis and the role of Akt kinase in both cell death and inflammatory
regulation.
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Introduction
Necroptosis is a form of regulated cell death that displays all the
major hallmarks of necrosis [1]. A growing number of studies have
implicated necroptosis in a wide range of animal models of human
disease, including brain, heart and retinal ischemia-reperfusion
injury, acute pancreatitis, brain trauma, retinal detachment, and
Huntington’s disease [2,3]. Importantly, several recent studies
have linked necroptosis to models of inflammation including
intestinal inflammation and systemic inflammatory response
syndrome (SIRS) [4,5,6]. The discovery of a regulated form of
necrotic death could uncover molecular targets amenable to
pharmacological intervention for the treatment of various condi-
tions.
A complex consisting of two related Ser/Thr kinases, RIP1 and
RIP3, plays a critical role in the initiation of necroptosis in
multiple systems [7,8,9]. A recent genome wide siRNA screen for
mediators of necroptosis induced by the pan-caspase inhibitor
zVAD.fmk in mouse fibrosarcoma L929 cells, revealed a broad
and diverse cellular network of 432 genes that may regulate this
process [10]. These data provided important confirmation of the
highly regulated nature of necroptosis and revealed the first insight
into the full repertoire of mediators of this form of cell death.
However, the specific signaling pathways activated during
necroptosis and their connections to RIP1 and RIP3 remain
poorly understood. Several recent studies [10,11,12,13,14] have
suggested that JNK kinase activation plays an important role
during necroptosis in L929 cells downstream from RIP1 kinase.
For example, the transcription factor c-Jun, a key cellular target of
JNK activity, was one of the hits in the genome wide siRNA screen
[10]. Activation of JNK in L929 cells has been linked to autocrine
TNFa synthesis, activation of oxidative stress and induction of
autophagy, all of which contribute to necroptosis. Importantly,
RIP1 kinase dependent activation of JNK and TNFa production
has recently been described to be independent of its role in
necroptosis [15]. Curiously, Akt kinase, a key pro-survival
molecule and a well-established inhibitor of apoptotic cell death,
has also recently been linked to necroptosis in L929 cells [16],
where insulin-dependent activation of Akt was suggested to
promote necroptosis by suppressing autophagy. This conclusion
was unexpected, since several reports from different groups,
including ours, have established that autophagy promotes, rather
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than suppresses, zVAD.fmk-induced necroptosis in L929 cells
[11,14,17]. This raised the possibility that Akt controls more
general mechanisms that contribute to the execution of necrop-
tosis. Furthermore, the key question of whether insulin-dependent
Akt activity solely provides an environment conducive for
necroptosis or if Akt activation is an intrinsic component of
necroptosis signaling that is linked to RIP1 kinase has not been
explored.
In this study, we expanded these observations to delineate the
specific contributions and molecular ordering of the Akt and JNK
pathways downstream from RIP1 kinase during necroptosis. Our
data reveal that Akt is activated through RIP1 kinase-dependent
Thr308 phosphorylation during necroptosis in multiple cell types.
Furthermore, we found that downstream Akt signaling through
mTORC1 and S6 contributes to the activation of necroptosis and
TNFa production. We found that the Akt pathway serves as a
critical link between RIP1 kinase and JNK activation in L929 cells.
Further data suggested that in multiple other cell types including
FADD deficient Jurkat cells, RAW and J774.1 macrophage cell
lines, and mouse lung fibroblasts Akt provides a key link to TNFa
production, but is dispensible for cell death per se. Overall, our
results reveal a specific and novel role for the Akt pathway in
regulated necrosis and necrosis-associated inflammatory signaling.
Results
Basic Fibroblast Growth Factor Promotes Necroptosis in
L929 Cells
It has been established that mouse fibrosarcoma L929 cells
undergo necroptotic cell death following stimulation with TNFa
[10,17]. In addition, inhibition of caspase-8 activity alone, either
through siRNA knockdown or by using the pan-caspase inhibitor,
zVAD.fmk, is sufficient to trigger necroptosis in these cells [10,14].
Interestingly, while necroptosis was initially identified as a back-up
form of cell death triggered by pro-apoptotic stimuli in the
presence of apoptosis inhibitors [17], recent analysis of physiolog-
ical cell death during mouse development has suggested that the
loss of apoptotic regulators, such as caspase-8 and FADD
[18,19,20], leads to robust induction of necroptosis and death of
E10.5 embryos even though apoptosis is not normally induced in
wild type embryos. These data are reminiscent of the observations
in L929 cells where the loss of caspase activity in healthy cells is
sufficient to trigger necroptosis and prompted us to explore the
extrinsic or intrinsic cellular factors that promote necroptosis once
caspase-8 activity, which cleaves and inactivates RIP1 kinase and
the RIP1 deubiquitinase CYLD [21,22], is removed in L929 cells.
Consistent with a previous report [16], we found that serum
starvation of L929 cells prevented necroptosis in response to
zVAD.fmk (Fig. 1A). The addition of growth factors, such as
bFGF, restored zVAD.fmk induced death under serum free
conditions (Fig. 1B). Interestingly, this does not reflect a generic
requirement for growth factor signaling, as only some growth
factors (bFGF and IGF-1, but not EGF and PDGF) promoted
death (Fig. 1B). Furthermore, growth factor-dependent necroptosis
required the inhibition of caspase activity, as bFGF alone did not
induce cell death (Fig. 1C). In contrast, TNFa triggered
necroptosis equally efficiently in the absence of serum (Fig. 1A),
suggesting that either growth factors and zVAD.fmk or TNFa are
required for necroptotic death in L929 cells.
Previously we described the development of 7-Cl-O-Nec-1
(Nec-1) as a potent and selective inhibitor of RIP1 kinase and
necroptosis (Fig. S1A) [23,24]. Recently, its selectivity has been
further validated against a panel of more than 400 human kinases
[15]. This inhibitor efficiently blocked growth factor/zVAD.fmk-
induced necroptosis under serum free conditions in L929 cells and
both zVAD.fmk and TNFa-induced necroptosis under full serum
conditions (Fig. 1B, S1B). To further validate the role of RIP1, we
used an inactive analog, 7-Cl-O-Nec-1i (Nec-1i) (Fig. S1A), which
contains an extra N-methyl group that leads to almost complete
loss of RIP1 kinase inhibitory activity in vitro [23]. Nec-1i was
unable to protect L929 cell death under serum condtions treated
with zVAD.fmk or TNFa (Fig. S1B) or serum free conditions
treated with bFGF/zVAD.fmk (Fig. S1C). This confirms that
RIP1 kinase is responsible for necroptosis in L929 cells under both
serum and serum free conditions.
We next examined whether bFGF contributes to zVAD.fmk-
induced necroptosis under normal serum conditions (10% FBS).
We used two bFGF receptor tyrosine kinase inhibitors (PD173074
and PD166866), and determined that inhibition of bFGF signaling
strongly inhibited zVAD.fmk-induced necroptosis under normal
serum conditions (Fig. 1D). In contrast, neither bFGF receptor
inhibitor was able to attenuate TNFa-induced necroptosis
(Fig. 1D), consistent with growth factors being dispensable for
this pathway (Fig. 1A). Overall, these data suggest that the
induction of necroptosis by zVAD.fmk is promoted by bFGF
under both serum and serum free conditions. The induction of
necroptosis, however, is not a simple consequence of growth factor
signaling since not all growth factors allowed death to occur.
Instead, specific signaling events mediated by particular growth
factors appear to contribute to necroptotic death.
RIP1 Kinase-dependent Activation of Akt Contributes to
Necroptosis
Given our observation that growth factors are important for
zVAD.fmk induced death, we examined the contribution of
several pathways, including MAPK pathways and Akt, which are
known to be activated following growth factor receptor activation
(Fig. 2A). Inhibition of Akt (Akt inhibitor VIII) strongly protected
the cells from growth factor-sensitive necroptosis induced by
zVAD.fmk [16] as well as cell death triggered by bFGF or IGF-1/
zVAD.fmk under serum free conditions (Fig. 2B). Inhibition of Akt
also protected the cells from growth-factor insensitive death by
caused by TNFa (Fig. 2A). Consistent with previous reports, the
JNK inhibitor SP600125 protected the cells from both zVAD.fmk
and TNFa induced death (Fig. 2A,B and Fig. S2A) [12,14]. In
contrast, inhibition of two other MAPKs, p38 and ERK,
previously reported not to be activated during necroptosis [14],
did not protect from either zVAD.fmk or TNFa induced death
(Fig. 2A).
Next, we used two approaches to further validate the role of Akt
in necroptotic cell death. First, two additional Akt inhibitors, a
highly specific, allosteric kinase inhibitor MK-2206 [25] and
triciribine (TCN) [26], which blocks membrane translocation of
Akt, both attenuated cell death (Fig. S2B). Secondly, simultaneous
knockdown of Akt isoforms Akt1 and Akt2 using siRNAs protected
cells from necroptosis induced by both zVAD.fmk and TNFa
(Fig. 2C). No expression of Akt3 was seen in L929 cells (Fig. S2C)
and, consistently, Akt3 siRNA had no additional effect on
necroptosis. Our results confirmed that Akt plays a key role in
necroptosis induced by multiple stimuli in L929 cells.
To understand the activation of Akt and JNK under necroptotic
conditions, we examined the changes in Akt and JNK phosphor-
ylation at 9 hrs post zVAD.fmk and TNFa stimulation. This time
point was chosen because it reflects the early stage of cell death in
our system (Fig. S3A, B). Following stimulation with either
zVAD.fmk or TNFa we observed a robust increase in Akt
phosphorylation at a known major activation site, Thr308
(Fig. 3A). Interestingly, we did not observe concomitant phos-
Interplay of Akt and JNK in Necroptosis Control
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phorylation changes in the second major activation site of Akt,
Ser473. We also observed an increase in the phosphorylation of
both the p46 and p54 isoforms of JNK and its major substrate c-
Jun (Fig. 3A). These data indicate that both Akt and JNK are
activated under necroptotic conditions.
The RIP1 kinase inhibitor, Nec-1, completely prevented the
increase in Thr308 Akt phosphorylation, while Nec-1i did not
(Fig. 3A, Fig. S1D). Similarly, Nec-1 prevented the induction of
JNK phosphorylation in response to zVAD.fmk and substantially
reduced this change after TNFa addition. We observed some
changes in total protein levels of JNK and c-Jun following
necroptotic stimulation. Some of these changes, e.g. zVAD.fmk-
induced increase in c-Jun, were also attenuated by Nec-1.
Importantly, Nec-1 did not alter the basal phosphorylation levels
of either Akt or JNK (Fig. 3A). This established that Akt Thr308
and JNK phosphorylation during necroptosis is RIP1 dependent.
Interestingly, we discovered that the phosphorylation of Akt
Thr308, JNK and Jun are late events following zVAD.fmk
stimulation (Fig. 3B) that coincide with the onset of necroptosis at
6 hr post-stimulation (Fig. S3A). To better understand the
contributions of growth factors and RIP1 kinase to necroptotic
regulation of Akt, we next analyzed the time course of these
phosphorylation changes under serum free conditions. We found
that the addition of bFGF alone or in combination with
zVAD.fmk led to a substantial rapid and transient increase in
both Thr308 and Ser473 phosphorylation of Akt as well as JNK
and c-Jun at 15 minutes, reflecting the expected response to
growth factor stimulation (Fig. 3C). Significantly, the combination
of bFGF/zVAD.fmk, but not bFGF alone, also caused a robust,
second, delayed increase in the phosphorylation of Thr308, but
not Ser473, of Akt as well as a delayed increase in the
phosphorylation of JNK and Jun. Furthermore, Nec-1 had no
significant effect on the early increase in both Akt and JNK/c-Jun
phosphorylation triggered by both bFGF and bFGF/zVAD, while
Nec-1, but not its inactive analog Nec-1i (Fig. S1E), efficiently
blocked the bFGF/zVAD increase at 6–9 hr (Fig. 3D), suggesting
that only the delayed activation of Akt and JNK is specific for
necroptosis and dependent on RIP1 kinase activity. Similarly,
IGF/zVAD, which also promoted cell death under serum free
conditions, produced a delayed increase in Thr308 phosphoryla-
tion on Akt, while IGF alone caused solely an early, transient
increase in phosphorylation (Fig. S3C). We confirmed the kinetics
of the Akt Thr308 and Ser473 phosphorylation changes using a
quantitative ELISA assay, which also showed a robust delayed
necroptosis-specific RIP1-dependent increase in Akt Thr308
phosphorylation (Fig. S3D, E). Taken together, these results
indicate that the observed delayed increases in Akt and JNK
phosphorylation, preceding the onset of cell death, represent
specific consequences of necroptotic signaling downstream from
RIP1 kinase.
TNFa Induces Delayed Akt Thr308 Phosphorylation and
Necroptosis Independent of Growth Factor Stimulation
Consistent with TNFa inducing necroptosis independently of
growth factors (Fig. 1A), FGFR inhibitors did not attenuate TNFa-
induced changes in Akt or JNK phosphorylation, while efficiently
preventing these changes in response to zVAD.fmk (Fig. S4A).
Furthermore, addition of TNFa led to comparable late activation
of Akt p308 signal under both normal and serum free conditions
(Fig. S4B, C), indicating that TNFa signaling to Akt Thr308 is
growth factor-independent. In contrast, activation of JNK by
TNFa followed different kinetics from zVAD.fmk-induced chang-
es. TNFa treatment caused an early and robust increase in the
phosphorylation of JNK and c-Jun. Nec-1 did not affect this early
increase, however, it reduced levels of pJNK/Jun at the late, 9 hr
time point (Fig. S4B, C). This again separated early RIP1-
independent changes, which likely reflect the ability of additional
Figure 1. bFGF and IGF-1 promote necroptosis in concert with zVAD.fmk. (A) L929 cells were treated with TNFa or zVAD.fmk under normal
serum (10% FBS) or serum free conditions. Cell viability was determined after 24 hr using the CellTiter-Glo Viability assay. The concentrations of all
necroptosis-inducing agents are listed in the Materials and Methods section or indicated in the figures. (B) Cells were treated with zVAD.fmk, the
indicated growth factors, and Nec-1 under serum free conditions for 24 hrs followed by measurement of cell viability. (C) Cells under serum free
conditions were treated with FGF, zVAD.fmk, or both for 24 hrs followed by viability assay. (D) Cell death was induced by zVAD.fmk or TNFa under full
serum condition in the presence of 2 mM PD173074 and 20 mM PD166866. In all graphs, average6SD was plotted.
doi:10.1371/journal.pone.0056576.g001
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upstream kinases, such as Ask1 to activate JNK [27], from the late
RIP1 kinase-dependent necroptotic signaling.
Late Increase in Akt Thr308 Phosphorylation Contributes
to the Induction of Necroptotic Cell Death
We next investigated if the delayed RIP1 kinase-dependent
increase in Akt Thr308 phosphorylation functionally contributes
to the execution of necroptotic cell death. Firstly, PDGF/
zVAD.fmk, which cannot induce necroptosis (Fig. 2A), triggered
only the initial, rapid Akt and JNK phosphorylation changes and
not the delayed activation (Fig. 4A), indicating that late, rather
than early Akt phosphorylation correlates with necroptosis.
Secondly, we saw that the ability of the Akt inhibitor to protect
cells from necroptosis rapidly declined after 6 hrs of stimulation
with zVAD.fmk, TNFa or bFGF/zVAD.fmk and no protection
was observed when the inhibitor was added at 9 hrs (Fig. 4B,C).
This time frame coincides with the timing of the secondary Akt
Thr308 phosphorylation. Finally, we terminated the bFGF signal
one hour after addition of bFGF by the addition of PD173074.
This allowed us to retain early Akt activation, but to suppress the
secondary increase (Fig. 4D). Both pre-addition and delayed
addition of PD173074 fully prevented necroptosis (Fig. 4E).
Overall, these data, while correlative, indicate that early Akt
activation is insufficient to promote necroptosis and are strongly
supportive of an important role for the delayed activation of Akt in
the induction of necroptotic cell death.
The Akt Signaling Pathway Contributes to the Regulation
of Necroptosis
We next determined whether the necroptosis-associated in-
crease in Thr308 phosphorylation results in an increase in Akt
kinase activity. Under necroptotic conditions, we observed an
increase in the phosphorylation of multiple known Akt substrates
(Forkhead box class O (FoxO) proteins, GSK-3 kinases and mouse
double minute 2 (MDM2)) as well as downstream molecules (p70
ribosomal protein S6 Kinase (p70S6K), S6) (Fig. 5A). In some
cases (FoxO1, FoxO4, MDM2), a robust increase was observed. In
other cases (FoxO3a, GSK-3a/b, p70S6K and its substrate S6),
the changes were less pronounced (Fig. 5A). The timing of the
phosphorylation changes paralleled the increase in Akt phosphor-
ylation (Fig. 5B, S5A, B). In the case of pFoxO1 we occasionally
observed a shift in migration rather than an increase in band
intensity (e.g. comparing Fig. 5A and B), suggesting that
phosphorylation events in addition to Thr24 take place during
necroptosis. Notably, in all cases the necroptosis-associated
increases in Akt substrates were abrogated by Nec-1 (Fig. 5A,
Fig. S5A, B). Overall, these data suggested that a significant part of
the ‘‘canonical’’ Akt signaling network is activated at the onset of
necroptotic cell death in a RIP1 dependent fashion.
Akt kinase is considered to be a pro-survival protein that inhibits
apoptosis through the control of multiple effectors including
mTORC1, GSK-3 and others [28]. An important question is
whether these same molecules reverse their pro-survival roles
during necroptosis. We found that inhibition of mTORC1 by
rapamycin, an inhibitor of the mTOR co-factor Raptor [29],
protected cells from necroptosis (Fig. 5C). Similarly, the direct
mTOR kinase inhibitor Torin1 [30] and the dual PI3K/mTOR
inhibitor PI-103 [31] also efficiently inhibited necroptosis (Fig. 5C).
Knockdown of mTOR using siRNA further validated the small-
molecule inhibitor data indicating a role for mTOR in necroptosis
by protecting cells from both zVAD.fmk and TNFa induced death
(Fig. 5D).
mTORC1 regulates translation through activation of p70S6
kinase and, subsequently, ribosomal protein S6 [32]. Notably, a
genome-wide siRNA screen [10] suggested an important role for
protein translation in necroptosis. Consistently, we found that the
small molecule inhibitor of p70S6K PF-4708671 [33] attenuated
necroptosis at the concentrations required to block S6 phosphor-
ylation (Fig. S5C, D). Partial siRNA knockdown of S6 protein
attenuated necroptosis as well (Fig. S5E), suggesting that
translational control by p70S6K/S6 may play a role in
necroptosis. Overall, while the full repertoire of Akt targets during
necroptosis remains to be fully explored, our data provide
evidence that the activity of an anti-apoptotic branch of Akt
signaling can promote necroptosis.
RIP1 kinase, Akt, mTORC1 and JNK control the upregulation of TNFa
accompanying necroptosis. Hitomi et al. [10] have recently reported
that the induction of necroptosis by zVAD.fmk in L929 cells is
associated with increased synthesis of TNFa, which potentiates cell
death. Therefore, we examined whether Akt and its effectors
contribute to TNFa synthesis. Consistent with a RIP1-dependent
increase in TNFa protein (Fig. S6A, B), we found that TNFa
Figure 2. Akt contributes to necroptosis induced by zVAD.fmk
and TNFa. (A,B) Necroptosis was induced by zVAD.fmk or TNFa (full
serum, A) or growth factors/zVAD.fmk (serum free, B) in the presence of
inhibitors of Akt (Akt inhibitor VIII), JNK (SP600125), p38 (PD169316),
and Erk (UO126). Cell viability was determined after 24 hrs. (C) L929
cells transfected with Akt1, Akt2, and Akt3 siRNAs for 72 hrs were
treated with zVAD.fmk or TNFa for 9 hrs. Cell viability and Akt
expression levels were determined after 24 hrs. In all graphs,
average6SD was plotted.
doi:10.1371/journal.pone.0056576.g002
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Figure 3. RIP1 kinase-dependent phosphorylation of Akt and JNK during necroptosis. (A) L929 cells were treated with zVAD.fmk or TNFa
for 9 hr, followed by western blotting with indicated antibodies. (B,C) L929 cells were treated with zVAD.fmk (B) or bFGF/zVAD.fmk (serum free
conditions, C) and samples were collected at the indicated time points for western blot. (D) Nec-1 was added to the cells stimulated with bFGF or
bFGF/zVAD (serum free conditions) for 15 min or 9 hr followed by western blot with the indicated antibodies.
doi:10.1371/journal.pone.0056576.g003
Figure 4. Late Thr308 phosphorylation of Akt contributes to necroptosis. (A) L929 cells were treated with zVAD.fmk and bFGF or PDGF,
with or without Nec-1, for the indicated periods of time. (B,C) L929 cells were stimulated by zVAD.fmk or TNFa (B) or bFGF/zVAD.fmk under serum
free conditions (C). Akt inh. VIII was added 15 min before necroptotic stimulation (Pre) or at indicated times after stimulation. Viability was measured
24 hr after activation of necroptosis. (D) L929 cells were stimulated with bFGF/zVAD under serum free conditions. PD173074 was added 15 min
before or 1 hr after FGF/zVAD. Samples for western blot were collected at 15 min and 9 hr time points. (E) Cells were pretreated with PD173074 or it
was added 1 hr after bFGF/zVAD.fmk, followed by viability assessment at 24 hr. In all graphs, average6SD was plotted.
doi:10.1371/journal.pone.0056576.g004
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mRNA levels increased during necroptosis in L929 cells in a RIP1
(Fig. S6C. Under serum free conditions, bFGF alone triggered
some induction of TNFa mRNA, while its combination with
zVAD.fmk (but not zVAD.fmk alone) caused a pronounced
further increase (Fig. 6A). Conversely, PDGF caused a modest
upregulation of TNFa mRNA, which was not further increased in
the presence of zVAD.fmk (Fig. 6A), demonstrating that activation
of necroptosis is specifically accompanied by a marked increase in
autocrine TNFa synthesis.
Further analysis suggested that both Akt and mTORC1
contribute to the upregulation of TNFamRNA during necroptosis
as both small-molecule inhibition and siRNA knockdown of Akt
and mTOR reduced TNFa mRNA levels in necroptotic cells
(Fig. 6B,C,D). Notably, RIP1 and Akt inhibitors had no effect on
the levels of TNFa mRNA in control cells or in the cells stimulated
with bFGF alone (Fig. 6A,B, Fig. S6C), suggesting that these
kinases specifically mediate necroptosis-dependent increase in
TNFa synthesis.
Akt and mTORC1 Control the Activation of JNK during
Necroptosis
JNK is a well-established regulator of TNFa synthesis in a
variety of systems [13,14,15,34]. Therefore, the ability of Akt and
mTORC1 inhibitors to block the increase in TNFa mRNA lead
us to examine their role in the activation of JNK during
necroptosis. Knockdown of Akt isoforms Akt1 and Akt2 or
inhibition of Akt prominently suppressed the necroptosis depen-
dent increase in JNK and c-Jun phosphorylation (Fig. 6E, S6D,E)
suggesting that Akt may provide a link between RIP1 and JNK
activation. Importantly, inhibition of Akt only inhibited the
delayed, but not the early, increase in bFGF/zVAD.fmk induced
JNK and c-Jun phosphorylation (Fig. S6F). Knockdown of
mTOR, rapamycin and the p70S6K inhibitor PF-4708671 also
attenuated the necroptosis-associated increase in JNK and c-Jun
phosphorylation (Fig. 6F, S6E,G, Fig. S5D). Overall, these data
suggested that the Akt-mTORC1-S6K axis, acting downstream
from RIP1 kinase, is required for the increase in JNK activity
during necroptosis in L929 cells.
PI3-kinase and PDK1 Mediate the Increase in Akt Thr308
Phosphorylation Under Necroptotic Conditions
Typical regulation of Akt by growth factors involves its
recruitment to the plasma membrane, which is mediated by the
binding of the pleckstrin homology (PH) domain of Akt to the
product of PI3K, phosphatidylinositol-3,4,5-triphosphate (PIP3).
In the membrane, Akt is phosphorylated on Thr308 and Ser473
by 3-phosphoinositide dependent protein kinase-1 (PDK1) and
mTORC2 (or DNA-PK), respectively [35]. Since our results
showed that only Thr308 Akt phosphorylation is increased during
necroptosis, we next examined whether it is still dependent on
PI3K and PDK1. Inhibition of PI3K and PDK1 using the specific
inhibitors LY249002 and BX912 [36] resulted in the efficient
inhibition of cell death and Akt Thr308 phosphorylation (Fig.
S7A–D). Likewise, siRNA knockdown of PDK1 protected cells
from death and inhibited Akt Thr308 phosphorylation (Fig.
S7E,F) Therefore, PI3K and PDK1 activity is still required for
non-canonical Akt activation during necroptosis.
Figure 5. mTORC1 contributes to the regulation of necroptosis. (A) L929 cells were treated with zVAD.fmk or TNFa for 9 hr and harvested for
western blot. (B) Cell under serum free condition were treated with bFGF or bFGF/zVAD.fmk for the indicated amounts of time, followed by western
blotting using the indicated antibodies. (C) Necroptosis was induced by zVAD.fmk or TNFa in L929 cell in the presence of inhibitors of Akt(Akt inh.
VIII) and mTOR (rapamycin, Torin-1 and PI-103). (D) L929 cells with mTOR siRNA knockdown were harvested for western blot or treated with zVAD.fmk
or TNFa for 24 hrs. Cell viability was determined 24 hr after activation of necroptosis. In all graphs, average6SD was plotted.
doi:10.1371/journal.pone.0056576.g005
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Expression of Constitutively Active Akt, Rescues
Necroptosis Under Serum Free Conditions
We used L929 cells stably expressing constitutively active wild
type Akt1 (Myr-Akt) or the catalytically inactive mutant K179M in
order to further understand the contribution of growth factors and
RIP1 kinase to Akt activation during necroptosis. Constitutively
active Akt1 (Myr-Akt) was generated as previously described [37]
by the addition of a myristoylation signal which provides
constitutive localization to the plasma membrane and by the
deletion of the auto-inhibitory PH domain (Fig. 7A) resulting in an
Akt that is active under serum free. It is important to note that the
cells expressing Myr-Akt were viable, grew in a manner
indistinguishable from the empty vector control cells, and were
not triggered to induce necroptosis by serum starvation (Fig. 7B).
This indicates that active Akt alone is not sufficient to induce
necroptotic cell death. Under serum free conditions Myr-Akt, but
not the K179M mutant, fully restored zVAD.fmk-induced
necroptosis (Fig. 7A,B). Nec-1 prevented both Myr-Akt dependent
cell death and the necroptosis-specific delayed increase in Akt
Thr308 phosphorylation (Fig. 7B,C). Myr-Akt also allowed other
zVAD.fmk-dependent events, including activation of JNK and c-
Jun phosphorylation (Fig. 7C) and upregulation of TNFa mRNA
(Fig. 7D) to occur under serum free conditions, confirming an
important role for Akt at the apex of necroptotic signaling. These
data demonstrated that the presence of active and membrane
localized Akt is sufficient to uncouple Akt activation during
necroptosis from growth factor signaling. RIP1 kinase was still able
to regulate Akt activation during necroptosis, suggesting that
growth factors and RIP1 kinase provide two independent inputs
required for Akt changes during necroptosis.
RIP1 kinase-dependent Thr308 phosphorylation of Myr-Akt
during necroptosis increased Myr-Akt activity as it did with
endogenous Akt (Fig. 5). Phosphorylation of many previously
described Akt substrates was increased upon the expression of
Myr-Akt, but not the K179M mutant, confirming that these
molecules are Akt substrates in L929 cells (Fig. 7C). The effect of
zVAD.fmk on their phosphorylation varied, likely due to the
increased basal activity of Myr-Akt. Some substrates, including
p70S6K, S6, GSK-3 and FoxO4, were fully phosphorylated even
in the absence of zVAD.fmk. On the other hand, phosphorylation
of FoxO1 and MDM2 was significantly increased in the presence
of zVAD.fmk, indicating that necroptotic Thr308 phosphorylation
of Myr-Akt still promoted its activity.
Figure 6. Akt and mTORC1 control autocrine TNFa synthesis and JNK activation during necroptosis. (A) Cells were treated under serum
free conditions with bFGF or PDGF with or without zVAD.fmk for 9 hr, followed by qRT-PCR analysis of mTNFa. Data was normalized to mouse 18S
RNA. (B) Necroptosis was induced by zVAD.fmk or TNFa in cells treated with Nec-1, rapamycin (rapa), or Akt inh. VIII inh. followed by qRT-PCR analysis
of TNFa mRNA levels. (C-F) L929 cells with siRNA knockdown of Akt isoforms (C,E) or mTOR (D,F) were stimulated with zVAD.fmk or TNFa for 9 hr,
followed by qRT-PCR analysis of mTNFa (C,D) or western blot (E,F). In all graphs, average6SD was plotted.
doi:10.1371/journal.pone.0056576.g006
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Figure 7. Over expression of constitutively active Akt restores necroptosis under serum free conditions. (A,B) L929 cells were stably
infected with empty MSCV retrovirus or viruses encoding Myr-Akt or the catalytically inactive Myr-Akt K179M. Necroptosis was induced by the
addition of zVAD.fmk under serum free conditions (A) or serum or serum free conditions with Nec-1 (B). Viability assays were performed after 24 hr.
(C) Myr-Akt and Myr-Akt K179M cells were treated with zVAD.fmk and/or Nec-1 under serum free conditions for 9 hr, followed by western blot using
the indicated antibodies. Endogenous Akt (,) and Myr-Akt (*) bands are indicated. (D) L929 cells, stably infected with Myr-Akt and Myr-Akt K179KM,
were stimulated with zVAD.fmk for 9 hr under serum free conditions. TNFa mRNA levels were determined by qRT-PCR and normalized using mouse
18S RNA. (E-G) L929 cells expressing Myr-Akt and Ala and Asp mutants of Thr308 and Ser473 were treated with zVAD.fmk under serum free
conditions, followed by viability assay at 24 hr (E), western blot at 9 hr (F), or evaluation of TNFa mRNA levels by qRT-PCR at 9 hrs (G). In all graphs,
average6SD was plotted.
doi:10.1371/journal.pone.0056576.g007
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Under serum free conditions all zVAD.fmk-induced down-
stream events (cell death, JNK activation, TNFa production) were
dependent on the over expressed Myr-Akt. This allowed us to
examine the effects of other Akt mutations on necroptosis. First,
we found that membrane localization of Akt is required. Full
length Akt or a mutant lacking both the PH domain and the Myr
tag did not support the activation of cell death or increased
Thr308 phosphorylation following zVAD.fmk addition under
serum free conditions (Fig. S8A,B). Second, we found a specific
and critical role for Thr308 phosphorylation in the regulation of
the necroptotic functions of Akt. It has been reported that Ala
mutations at Thr308 and Ser473 cause a reduction in the catalytic
activity of Akt, while Asp mutants increase activity [38]. We
examined the effect of Ala and Asp mutants at both sites during
necroptosis. In our hands, both Asp mutants displayed activity
comparable to wild type Akt, while both Ala mutants displayed
comparable decreases in activity (Fig. S8C). Despite similar
catalytic activities, Thr308 and Ser473 mutants displayed major
differences in their ability to promote necroptotic changes
(Fig. 7E,F,G). As expected, the S473D mutant, which was
phosphorylated on Thr308 after the addition of zVAD, displayed
only slightly reduced activity, while S473A was significantly less
active in all aspects of necroptosis. S473A was unable to be
efficiently phosphorylated on Thr308 possibly due to the inability
of the Ala mutated 473 site to be phosphorylated and provide a
docking site for PDK1 to phosphorylate Thr308 [39]. Strikingly,
both Ala and Asp mutants of Thr308 were significantly less active
in promoting cell death, phosphorylation of JNK and c-Jun, and
TNFa mRNA. This suggests that T308D, in spite of being an
active Akt construct, may not be a perfect mimic of phosphor-
ylation and this mutant form of the kinase may not have sufficient
activity to phosphorylate the entire repertoire of substrates in the
cells. When tested, T308D did not support the downstream
phosphorylation of several substrates that were phosphorylated by
the Myr-Akt construct in the presence of zVAD including FoxO1,
Foxo4, MDM2, and p70S6K (Fig. S8D). Our model, based on
these results, is that necroptosis-specific Thr308 phosphorylation
provides a critical link between necroptotic machinery and Akt
kinase, allowing Akt to phosphorylate substrates during necrop-
tosis, promote TNFa synthesis, JNK activation and eventual cell
death.
Akt Controls TNFa Production in Other Cell Types
After establishing the role of RIP1 kinase-dependent signaling to
Akt in L929 cells, we sought to expand our study to other cell types
that are known to undergo necroptotic cell death. Fas-associated
protein with death domain (FADD)-deficient Jurkat T lympho-
cytes and the macrophage cell lines (J774A.1 and RAW264.7) are
other models of necroptosis, which can be induced by stimulation
with TNFa or zVAD.fmk, respectively [17]. Similar to L929 cells,
a RIP1 kinase dependent increase in the phosphorylation of
Thr308 on Akt occurred during necroptosis (Fig. 8B,D,F) in these
cell types. Furthermore, TNFa mRNA levels were increased in
each of these cell types during necroptosis and efficiently inhibited
by both RIP1 and Akt inhibitors (Fig. 8A,C,E). However,
inhibition of Akt did not protect these cells from death (Fig.
S9A,B,C). These results indicate that regulation of autocrine
TNFa synthesis and necroptosis-associated inflammatory signaling
may be a more important function of Akt pathway activation by
RIP1 kinase in multiple cell types compared to its contribution to
cell death.
We next chose to look at the role of Akt in necroptosis in mouse
lung fibroblasts. Lung fibroblasts selected to survive after deletion
of all three Akt isoforms [40] were resistant to cell death induced
by the addition of TNFa and zVAD.fmk. Expression of
catalytically active Akt (Myr-Akt) in these cells restored TNFa
mRNA production in response to TNFa and zVAD.fmk (Fig. 8G)
without re-establishing cell death (Fig. S9D). Consistent with our
earlier Akt knockdown data, lung fibroblasts expressing endoge-
nous Akt1 or Akt2 were phosphorylated on Thr308 in response to
TNFa and zVAD.fmk (Fig. S9E) and in both cases robust RIP1-
dependent TNFa mRNA upregulation occurred under necropto-
tic conditions (Fig. 8H). These data further support the notion that
Akt activity is critical for autocrine TNFa synthesis, even in the
absence of necroptotic cell death, indicating an unexpected
differentiation between Akt-mediated inflammatory signaling
under necroptotic conditions and cell death per se.
Model of RIP1, Akt and JNK Dependent Signaling in
Necroptotic L929 Cells
In this study we investigated RIP1 kinase-dependent signaling
pathways using mouse fibrosarcoma L929 cells that die by
necroptosis when treated with the pan-caspase inhibitor
zVAD.fmk. Altogether, our results suggest that Akt kinase is
specifically engaged in signaling downstream from RIP1 kinase,
which leads to a selective increase in its phosphorylation on
Thr308, but not Ser473. According to our model (Fig. 9),
necroptosis-associated phosphorylation of Akt requires two distinct
signals. The first input, which is induced by growth factors, leads
to the plasma membrane localization of Akt. Expression of a
constitutively membrane-targeted Akt construct, Myr-Akt, over-
comes the requirement for growth factors. At the same time,
expression of Myr-Akt alone is not sufficient for the induction of
necroptosis. A second, RIP1 kinase-dependent input is required
for Thr308 phosphorylation of Akt in response to caspase
inhibition and is essential for the propagation of the necroptotic
signal.
Using Akt inhibitors, knockdown of Akt isoforms, and the
expression of Akt mutants, we showed that necroptotic activation
of Akt is indispensable for this form of cell death in L929 cells. We
also investigated downstream Akt-dependent pathways that
contribute to necroptosis. First, we demonstrated that selective
necroptotic phosphorylation of Thr308 of Akt is sufficient to
increase its activity towards a number of known substrates and Akt
effector pathways such as the mTORC1 pathway, which, in turn,
contributes to cell death. Second, our data suggested that Akt
activation provides a pivotal link connecting RIP1 kinase to known
downstream signaling and execution events in necroptotic L929
cells, namely, JNK activation and autocrine TNFa synthesis, a
critical event in necroptosis in L929 cells [15].
In order to further test our model, we examined Akt
phosphorylation after inhibition of a downstream kinase in the
pathway, JNK. However, we found that SP600125, which
protected L929 cells from death and inhibited TNFa production
(Fig. 2A,B S2A S10A), inhibited both basal and post-treatment
phosphorylation levels of Akt at both Ser473 and Thr308 (Fig.
S10B). It has been published that SP600125 is a somewhat non-
specific inhibitor that may inhibit the p110d subunit of PI3K [41]
and PDK1 [42]. Both of these off-target effects could inhibit basal
Akt phosphorylation levels, precluding the use of SP600125 in this
system.
Therefore, to examine the role of JNK, we switched to a more
specific JNK inhibitor, JNK inhibitor VIII [43], and siRNAs
against JNK1 and JNK2 (Fig. S10B–G). As expected, specific
inhibition or knockdown of JNK1/2 allowed phosphorylation of
Akt on Thr308 while inhibiting the phosphorylation of c-Jun at
Ser63 (Fig. S10B,E), agreeing with our model. It did not, however,
lead to a reduction in TNFa production or cell death (Fig.
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S10C,D,F,G), suggesting that earlier data with SP600125 protec-
tion (Fig. 2) could reflect off-target effects of this molecule, rather
than JNK inhibition. Previous reports also suggested a critical role
for c-Jun in necroptosis and autocrine TNFa synthesis [13,14,15]
and we confirmed these conclusions using c-Jun siRNA knock-
down (Fig. S10H–J). Notably, in this case, Thr308 phosphoryla-
tion was reduced after the induction of necroptosis. Thus,
autocrine TNFa production, dependent on c-Jun, may create a
feedback loop that contributes to the delayed activation of Akt. It is
also important to note that we observed an overall increase in the
protein level of c-Jun after treatment of L929 cells with zVAD.fmk
or TNFa, which was both Akt and mTOR-dependent (Fig. 6E,F).
These new data led us to an unexpected, but important conclusion
that c-Jun is critical for necroptosis, while JNK activity may serve
as a useful marker of pathway activation, but may be either
redundant (e.g. phosphorylation of c-Jun on a site other than
Ser63 may occur [44]) or dispensable functionally. In addition,
researchers need to use caution when using SP600125 due to
potantial off-target effects.
Discussion
Altogether, our results suggest that Akt kinase is specifically
engaged in the signaling downstream from RIP1 kinase, which
exerts its activity through promoting a selective increase in Akt
phosphorylation on Thr308. This provides a link connecting
RIP1 kinase to downstream signaling and execution events
Figure 8. Akt signaling contributes to autocrine TNFa production in multiple cell types. FADD deficient Jurkat cells were treated with
TNFa followed by measurement of (A) human TNFa mRNA levels by qRT-PCR and normalized using human 18S RNA or (B) western blot at 9 hr. RAW
264.7 or J774A.1 cells were treated with zVAD.fmk (100 uM or 50 uM respectively) followed by (C,E) measurement of TNFa mRNA levels by qRT-PCR
or (D,F) western blot at 9 hr. (G) Akt null mouse lung fibroblasts expressing Myr-Akt or K179M were treated with zVAD.fmk and TNFa followed by
measurement of TNFa mRNA levels by qRT-PCR at 9 hr. (H) Mouse lung fibroblasts expressing only endogenous Akt1 or Akt2 were treated with
zVAD.fmk and TNFa followed by measurement of TNFa mRNA levels by qRT-PCR at 9 hr.
doi:10.1371/journal.pone.0056576.g008
Figure 9. Model of RIP1, Akt and JNK dependent signaling in
necroptotic L929 cells. Akt phosphorylation at Thr308 during
necroptosis requires inputs from both growth factors and RIP1 kinase.
Downstream from Akt, JNK activation leads to TNFa synthesis.
Activation of Akt during necroptosis also leads the phosphorylation
of several known Akt substrates, such as mTOR, which contribute to the
execution of necroptotic death in L929 cells.
doi:10.1371/journal.pone.0056576.g009
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during necroptosis in L929 cells, including JNK activation,
autocrine TNFa synthesis and eventual cell death. According to
our model, phosphorylation of Akt requires two distinct signals.
The first input, which is induced by growth factors, leads to the
plasma membrane localization of Akt. Expression of constitu-
tively active membrane-targeted Myr-Akt overcomes this re-
quirement. At the same time, expression of Myr-Akt is not
sufficient for the induction of necroptosis or efficient activation of
JNK and TNFa synthesis. A second, RIP1 kinase-dependent
input is required for Thr308 phosphorylation of Akt, which in
turn is required for necroptotic signaling. Necroptotic phosphor-
ylation of Thr308 of Akt is sufficient to increase its activity
towards a number of known substrates in L929 cells and our
data reveal that the Akt effector pathway downstream of
mTORC1 contributes to necroptosis, thereby identifying a new
mediator of this form of cell death.
Our results raise some important mechanistic questions
relevant to the specific regulation of Akt during necroptosis.
First, what is the mechanism of the RIP1-dependent increase in
Akt Thr308 phosphorylation? One possibility is that RIP1 kinase
inhibits a phosphatase that targets Thr308. To our knowledge,
PP2A is the only enzyme established to specifically dephosphor-
ylate this residue [45]. However, we did not observe any effect of
the PP2A inhibitor, okadaic acid, on Thr308 phosphorylation or
activation of necroptosis in L929 cells. Another possibility is that
the increase in Thr308 results from RIP1 kinase targeting PDK1,
Akt or scaffolding factors that bring these two kinases together.
Interestingly, we observed phosphorylation of Akt by recombi-
nant RIP1 kinase in vitro on Thr146, 195/197, and 435 and
Ser381 residues. Furthermore, mutating these residues to Ala in
Myr-Akt leads to the loss of its ability to promote necroptosis.
However, we were not able to confirm phosphorylation of these
residues on endogenous Akt in L929 cells using either mass
spectrometry or western blotting with a phospho-specific
antibody raised against Thr435 peptide, suggesting that direct
phosphorylation of Akt by RIP1 likely represents an in vitro
artifact and does not reflect endogenous regulation. Second, what
are the key substrates of Akt that promote necrotic death and
TNFa synthesis? On the one hand, our data suggest new roles
for Akt effector pathways mediated by mTORC1 in necroptotic
control. On the other hand, we have observed only modest
changes in mTORC1 activity under necroptotic conditions,
suggesting that additional Akt substrates are likely to be involved.
This warrants a re-evaluation of the roles of additional Akt
substrates in necroptotic death, since no such connections have
been established. Similarly, the mechanisms connecting
mTORC1 to JNK remain to be elucidated. While there are
some recent examples of mTORC1-dependent regulation of
JNK, e.g. following ER stress [46], the exact mechanisms during
necroptosis remain to be established. Given the activation of
JNK by TNFa and the importance of mTORC1-dependent
translational control in necroptosis, one possibility is that
mTORC1 contributes to the translation of TNFa and forms a
positive feed forward loop with JNK.
Akt’s role as a key inhibitor of apoptosis is well documented,
however, evidence of its contribution as a mediator of cell death
under various circumstances has begun to emerge as well
[45,47]. Our data demonstrates a new mode of necrosis-specific
regulation of Akt by RIP1 kinase. Importantly, while it is possible
that necroptosis-specific targets of Akt exist, this regulation
clearly involves a number of well established Akt targets
including mTORC1, and potentially, GSK-3, FoxO1/4, and
MDM2. Therefore, it may no longer be safe to assume that
activation of Akt universally reflects pro-survival signaling nor
that its inhibition will lead to more cell death. It is tempting to
speculate that rather than serving a universally pro-survival role,
the Akt pathway may function to promote cell fates alternative to
apoptosis, ranging from survival to non-apoptotic cell death. The
final decision between survival and death may depend on
additional, Akt-independent inputs, such as the status of RIP1
kinase, expression of particular oncogenic factors [45] or
excessive metabolic stress [47].
Another mechanism that should be considered in conjunction
with the regulation of cell death by Akt is autophagy. Akt
activation leads to the inhibition of autophagy through activation
of mTOR [48]. The role of autophagy in cell death in general is
very complex and it can both promote and inhibit necroptosis in
various situations. Several studies suggested that activation of
autophagy promotes necroptosis induced by zVAD.fmk in L929
cells [11,14]. Others, including ourselves in unpublished data,
have found that inihibition of autophagy promotes necroptosis by
TNFa [49]. This suggests that the inhibition of autophagy by Akt
or mTOR in our system may contribute to necroptosis induced
by TNFa, however, it is more difficult to reconcile with the
positive role of these proteins in zVAD-induced death. Clearly,
further identification of the factors differentiating between pro-
death and pro-survival autophagy in mammalian cells is required
to better understand its role in the regulation necroptosis by Akt
pathway.
Importantly, our data revealed that RIP1 kinase signaling to Akt
is a general feature of necroptotic signaling that is observed in
multiple cell types. At the same time, the significance of this
connection varies in a cell type specific fashion. Importantly, in
mouse lung fibroblasts, FADD-deficient Jurkat cells, and macro-
phages, Akt signaling contributed more prominently to an increase
in TNFa synthesis, rather than cell death per se, unlike its role in
L929 cells. A recent study [15] has demonstrated that, in addition
to its role in necroptosis, RIP1 plays an important role in
mediating the production of TNFa. These data emphasize the
emerging complexity of necroptotic signaling mechanisms and
highlight the major contribution of Akt to increased inflammatory
signaling, specifically accompanying this form of regulated necrosis
[5,6,10].
Robust inflammation is one of the most important consequences
of necrotic cell death as well as its regulated subtype, necroptosis,
both in vitro and in vivo [1,5,6,50,51]. Our results highlight an
important notion that inflammation not only passively accompa-
nies necroptosis in a variety of cellular systems by the virtue of
rapid loss of plasma membrane integrity characteristic for necrotic
cell death, but also that it is an intrinsic and regulated component
of necroptosis due to the specific activation of TNFa synthesis by
RIP1/Akt kinases. Therefore, this pathway may represent a new
molecular target for the inhibition of pathologic inflammatory
signaling. Initial in vivo data appears to support this notion. Two
recent papers showed that the loss of control over RIP1/RIP3
kinase activities by FADD and caspase-8 in epithelial cells
unleashes a feed forward cycle of necroptosis and TNFa
production, resulting in the development of intestinal inflamma-
tion in mice and, possibly, in patients with Crohn’s disease [4,5].
This increased production of TNFa during necroptosis may also
be important for acute necrotizing diseases, such as necrotizing
pancreatitis and acute bacterial infections, where hyper-acute
inflammation accompanying necrotic cell death is the primary
cause of multiple organ failure and patient death. Along these
lines, another recent paper by Duprez et al. has shown that RIP1
and RIP3 mediate the cellular damage introduced by TNF-
induced SIRS [6]. The role of RIP1 kinase in acute and chronic
inflammatory diseases warrants further investigation, as efficient
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and specific RIP1 kinase inhibitors may offer therapeutic benefit
for treating these conditions.
Materials and Methods
Reagents and Chemicals
Necrostatin analogs were synthesized as previously described
[23,24]. The following reagents and final concentrations (unless
otherwise specified in the text/figures) were used in the
experiments: Akt inhibitor VIII (10 mM, Calbiochem), MK-2206
(10 mM, Selleck Chem), Triciribine (100 mM, National Cancer
Institute), SP600125 (10 mM, Calbiochem), JNK inhibitor VIII
(10 mM, Calbiochem), UO126 (10 mM, Cayman Chem),
PD169316 (10 mM, Calbiochem), LiCl (10 mM, Sigma),
SB216763 (10 mM, Calbiochem), BX912 (10 mM, Axon Med
Chem), PF-4706871 (Sigma), rapamycin (100 nM, Santa Cruz),
PI-103 (10 mM, Calbiochem), Torin-1 (500 nM, gift of Dr.
Nathanael Grey (Harvard Medical School), LY249002 (10 mM,
Cell Signaling), PD173074 (2 mM, Cayman Chem), PD166866
(20 mM, Calbiochem), 4EGI-1 (50 mM, Calbiochem). Pan-caspase
inhibitor zVAD.fmk (20–30 mM) was purchased from Bachem.
Human and mouse TNFa (10 ng/ml), human bFGF (25 ng/ml),
EGF (50 ng/ml), PDGF-BB (20 ng/ml), and IGF-1 (50 ng/ml)
were from Cell Sciences or Peprotech. All other reagents were
from Sigma.
DNA
Cloning of Myr-Akt1, containing c-terminal FLAG tag, has
been described [52]. Myr-Akt1-FLAG was amplified by PCR and
subcloned into the BglII and EcoRI sites of pMSCV-puro
retroviral vector (Invitrogen). Mutant versions of Myr-Akt1 were
generated using the same strategy.
Antibodies
The following antibodies were used: phospho-Akt (Thr308)
(clone C31E5E) rabbit mAb, phospho-Akt (Ser473) (clone D9E)
XP rabbit mAb, Akt (pan) (clone C67E7) rabbit mAb, Akt1 (clone
C73H10) rabbit mAb, Akt2 (clone D6G4) rabbit mAb, Akt3 (clone
62A8) rabbit mAb, phospho-JNK (Thr183/Tyr185) (81E11)
rabbit mAb, SAPK/JNK rabbit pAb, phospho-c-Jun (Ser63) II
rabbit pAb, c-Jun (60A8) rabbit mAb, a-tubulin (clone DM1A)
mouse mAb, phospho-FoxO1 (Thr24)/FoxO3a (Thr32) rabbit
pAb, FoxO1 (L27) rabbit pAb, phospho-FoxO4 (Ser193) rabbit
pAb, FoxO4 rabbit pAb, phospho-MDM2 (Ser166) rabbit pAb,
phospho-GSK-3a/b (Ser21/9) rabbit pAb, phospho-p70 S6
Kinase (Thr389) (clone 108D2) rabbit mAb, phospho-S6 Ribo-
somal Protein (Ser235/236) (clone D57.2.2E) XP rabbit mAb, S6
Ribosomal Protein (clone 54D2) mouse mAb, phospho-4E-BP1
(Thr37/46) rabbit pAb, mTOR (clone 7C10) rabbit mAb, PDK1
rabbit pAb (all Cell Signaling), MDM2 rabbit pAb (Bioworlde).
QPCR Primers
Mouse TNFa: forward 59-CCCTCACACTCAGAT-
CATCTTCT-39, reverse 59-GCTACGACGTGGGCTACAG-
39;mouse 18S: forward 5-9 ATAACAGGTCTGTGATGCCCT-
TAG-3, reverse 59-CTAAACCATCCAATCGGTAGTAGC-
39;human TNFa: forward 59- ATGAGCACTGAAAGCAT-
GATCC-39, human TNFa: reverse 59-GAGGGCTGATTAGA-
GAGAGGTC-39; human 18S: forward 59- CAGCCACCCGA-
GATTGAGCA -3, human 18S: reverse 59-
TAGTAGCGACGGGCGGTGTG-39.
Cell Lines
L929 and FADD-deficient Jurkat cells were obtained from
ATCC. Lung fibroblasts were a generous gift of Dr. Philip Tsichlis
(Tufts University) [53]. J774A.1 (ATCC) cells and RAW264.7
(ATCC) cells were generous gifts of Junying Yuan (Harvard
University) and Alexander Poltorak (Tufts University), respective-
ly. Cells were maintained in DMEM supplemented with 10% fetal
bovine serum (FBS) and 1% antibiotic-antimycotic mixture
(Invitrogen). The mouse lung fibroblast media was additionally
supplemented with L-glutamine, non-essential amino acids, and
sodium pyruvate. Jurkat cells were maintained in RPMI1640,
supplemented with 10% FetalPlex (Gemini) and 1% antibiotic-
antimycotic.
Cell Viability Experiments
Cells were seeded into white clear bottom 96 well plates at the
density of 16104 cells/well and treated as described for western
blot experiments. Cell viability was determined using CellTiter-
Glo Cell Viability Assay (Promega). Experiments were performed
in duplicate or triplicate. Viability of the control untreated cells
was set as 100%. Relative viability of cells, induced to undergo
necroptosis and treated with the compound relative to the control
compound-treated cells, was determined and plotted to exclude
the possible effects of non-specific toxicity of the small molecules.
siRNA Knockdown
siRNAs were purchased from Dharmacon. Mouse ribosomal S6
protein (L-040893-00 and L-045791-00), mouse Akt1 (L-040709-
00), mouse Akt2 (L-040782-00), mouse Akt3 (L-040891-00),
mouse mTOR (L-065427-00), mouse PDK1 (L-040658-00), non-
coding control (D-001810-10-05), mouse Mapk8 (J-040128-05),
mouse Mapk9 (J-040134-05), mouse Jun (L-043776-00). siRNA
were transfected using RNAiMAX reagent (Invitrogen), according
to manufacturer’s recommendations. After 72 hr, cells were
treated with zVAD.fmk or TNFa for 9 hr (RNA or Western blot)
or 24 hr (cell viability).
Western Blot
For Western blot, 46105 adherent cells (16106 Jurkat cells)
were seeded into 35 mm2 dishes. After 24–48 hr, cells were
stimulated with 30 mM zVAD.fmk or 10 ng/ml mouse TNFa. For
treatments under serum free conditions, cells were serum starved
for 24 hr prior to the addition of growth factors, 20 mM
zVAD.fmk or 10 ng/ml mouse TNFa. Cells were harvested in
16RIPA buffer (Cell Signaling) supplemented with 50 mg/ml
phenylmethanesulfonylfluoride. After brief sonication, cell lysates
were spun down for 15 min at 14,0006rpm. Protein concentra-
tions were measured using the Pierce 660 nm Assay Reagent
(Pierce). Equal amounts of proteins were boiled for 5 min at 95uC.
Western blotting was performed according to standard protocols.
Briefly, SDS-PAGE gels were transferred to PVDF membrane,
blocked in 3% milk or 5% bovine serum albumin (BSA) in TBST
buffer for 30 min at room temperature. Primary antibodies were
incubated in 5%BSA/TBST overnight at 4uC. Secondary
antibodies were incubated in TBST for 30 min at room
temperature. Luminata (Millipore) ECL reagents were used to
develop the signals. In some cases, membranes were stripped using
OneMinute stripping buffer (GM Biosciences) and reprobed with
new antibodies.
qRT-PCR
Cells were treated as described for Western blots. Total RNA
was isolated using ZR Miniprep kit (Zymo Research). 1 mg of
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RNA was converted to cDNA using random primers (M-MuLV
cDNA kit, New England Biolabs). 1 mL of cDNA was used with
500 pM primers in qPCR reactions. Reactions were performs
using SYBRGreen 26Master mix (SABiosciences) in a Light-
Cycler480 (Roche).
Stable Infection of Myr-Akt1
To generate MSCV retroviruses, HEK293FT cells (Invitrogen)
were transfected with 2 mg of viral DNA and 1 mg of gal/pol and
VSV-G accessory plasmids in 6 well plates using GenJet
transfection reagent (Signagen Labs). Virus-containing media
was collected 72 hr later, filtered through 0.45 mm filter and
applied to L929 cells with 8 mg/ml polybrene. Cells were selected
and maintained in 10 mg/ml puromycin.
ELISAOne Assay
ELISAOne assays (TGRBio, Hindmarsh, Australia) were
performed according to manufacturer’s protocol with the follow-
ing modifications. Cell lysates were prepared in RIPA buffer as
described for Western blots. Five microliters of samples were
diluted in 45 mL of ELISAOne lysis buffer prior to analysis.
Primary antibodies to phopsho-Thr308 and phopsho-Ser473 were
incubated with the samples for 2 hr at room temperature. Primary
antibody to pan-Akt was incubated overnight at 4uC. Signals for
phospho-antibodies were normalized based on pan-Akt values.
TNFa ELISA
Mouse TNFa Quantikine ELISA assays (R&D Systems) were
performed according to manufacturer’s descriptions. Cell lysates
were prepared from 36106 cells plated and treated in a 10 cm2 dish.
In vitro Akt Kinase Assay
Akt kinase activity was measured using the Akt kinase assay kit
(nonradioactive) from Cell Signaling Technology. In brief, Myr-
Akt was immunoprecipitated from L929 cells using anti-FLAGM2
magnetic beads (Sigma). The in vitro assay was performed in the
presence of a GSK fusion protein substrate. Phosphorylation of the
GSK fusion protein was visualized by western blot.
Supporting Information
Figure S1 Necroptosis, induced by zVAD.fmk or TNFa,
was inhibited by Nec-1 but not Nec-1i. (A) Structures of 7-
Cl-O-Nec-1 (Nec-1) and the inactive analog, 7-Cl-O-Nec-1i (Nec-
1i). (B, D) L929 cells were treated with zVAD.fmk or TNFa in the
presence of Nec-1 or Nec-1i. (C, E) L929 cells were serum starved
followed by treatment with bFGF/zVAD.fmk in the prescence of
either Nec-1 or Nec-1i. (B, C) Cell viability was measured 24 hrs
post-treatment. (D, E) Cells were harvested for western blot 9 hrs
post-treatment. In all graphs, average6SD was plotted.
(TIF)
Figure S2 Akt contributes to death by necroptosis. (A)
L929 cells treated with zVAD.fmk or TNFa in the presence of the
JNK inhibitor, SP600125. Cells were analyzed for cell viability
24 hrs post-treatment. (B) L929 cells were treated with zVAD.fmk
or TNFa or bFGF/zVAD.fmk (serum free conditions) in the
presence of the Akt inhibitors (Akt inhibitor VIII 10 mM, MK2206
10 mM or Triceribine (TCN) 100 mM) and cell viability was
measured 24 hrs post-treatment. (C) Mouse lung fibroblasts
expressing either Akt1, Akt2, or Akt3 and L929 lysates were
harvested and western blotted using the indicated antibodies. In all
graphs, average6SD was plotted.
(TIF)
Figure S3 RIP1 kinase-dependent increase in Akt
Thr308 phosphorylation during necroptosis. (A, B) L929
cells treated with zVAD.fmk (A) or TNFa (B) for the indicated
period of time followed by assessment of cell viability. (C) Cells
were serum starved followed by treatment with IGF alone or IGF/
zVAD.fmk and samples were collected at the indicated time points
for western blot. (D,E) L929 cells were stimulated with bFGF and/
or zVAD.fmk and Nec-1 (N1) for the indicated periods of time.
Samples were analyzed using phospho-Thr308, phospho-Ser473
and pan-Akt ELISAOne assays. Phospho-signals were normalized
to pan-Akt. Fold induction over control cells is plotted. In all
graphs, average6SD was plotted.
(TIF)
Figure S4 Growth factor independent activation of Akt
Thr308 phosphorylation by TNFa. (A) Necroptosis was
induced by zVAD.fmk or TNFa in the presence of 2 mM
PD173074 or 20 mM PD166866 for 9 hrs followed by western
blot. (B,C) Cells were stimulated with TNFa under normal serum
(B) or serum free (C) conditions for the indicated periods of time
followed by western blot.
(TIF)
Figure S5 Downstream Akt signaling contributes to the
control of necroptosis. (A,B) L929 were stimulated with
zVAD.fmk (A) TNFa (B) for the indicated periods of time,
followed by western blot using indicated antibodies. (C,D) L929
were stimulated with TNFa or zVAD.fmk in the presence of the
indicated concentrations of PF-4706871. Viability was determined
after 24 hr (C). Western blot samples were collected after 9 hr (D).
(E) L929 cells were transfected with S6 siRNAs. After 48 hr,
necroptosis was induced by TNFa and zVAD.fmk for 24 hr. Inset,
levels of S6 were determined 48 hr after transfection. In all graphs,
average6SD was plotted.
(TIF)
Figure S6 Akt and mTORC1 contribute to autocrine
TNFa synthesis and JNK activation during necroptosis.
(A,B) L929 cells were stimulated by zVAD.fmk (A) and human
TNFa (B) for 9 hr. Cell lysates were subjected to mouse TNFa
ELISA. (C) L929 cells were stimulated by zVAD.fmk and TNFa in
the presence of either Nec-1 followed by measurement of TNFa
mRNA levels by qRT-PCR at 9 hr. (D) L929 cells were stimulated
by zVAD.fmk and TNFa in the presence of Akt inh VIII (10 mM),
MK2206 (10 mM) and TCN (100 mM) followed by western blot at
9 hrs. (E) Cells were stimulated with TNFa for 15 min or 9 hr in
the presence of Nec-1, Akt inh VIII and rapamycin. Western blot
samples were collected after 9 hr. (F) L929 cells were stimulated
with bFGF and zVAD.fmk (serum free conditions) for 15 min and
9 hr in the presence of Akt inh. VIII and analyzed by western blot.
(G) L929 cells were stimulated by zVAD.fmk in the presence of
Nec1, Akt inh VIII, or rapamycin followed by western blot at
9 hrs. In all graphs, average6SD was plotted.
(TIF)
Figure S7 PI3-Kinase and PDK1 mediate the increase in
Akt Thr308 phosphorylation under necroptotic condi-
tions. (A-D) L929 cells were stimulated by zVAD.fmk and TNFa
in the presence of LY249002 (A,B) or BX912 (C,D). Viability
assays were performed after 24 hr (A,C). Western blot samples
were collected after 9 hr. (B,D). (E,F) L929 cells were transfected
with PDK1 siRNAs. After 72 hr, necroptosis was induced by
TNFa or zVAD.fmk. Viability assays were performed after 24 hr
(E). Western blot samples were collected after 9 hr (F). In all
graphs, average6SD was plotted.
(TIF)
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Figure S8 Constitutively active Myr-Akt promotes ne-
croptosis under serum free conditions. (A,B) L929 cells
expressing Myr-Akt, full length Akt and a mutant lacking the PH
domain were treated with zVAD.fmk under serum free conditions,
followed by viability measurement at 24 hr (A) or western blot at
9 hr (B). * - non-specific band, coinciding with the migration of
Myr-Akt was detected by some lots of the p308 antibody. (C) L929
cells expressing Myr-Akt and Ala and Asp mutants of Thr308 and
Ser473 were immunoprecipitated from L929 cells and their
in vitro catalytic activity towards GSK-3b peptide was deter-
mined. (D) L929 cells expressing Myr-Akt or the T308D mutant
were treated with zVAD.fmk for 9 hrs under serum free conditions
followed by western blot analysis. In all graphs, average6SD was
plotted.
(TIF)
Figure S9 Akt signaling contributes to autocrine TNFa
production in multiple cell types. (A) FADD-deficient Jurkat
cells were treated with TNFa in the presence of Nec-1 or Akt inh
VIII. Cell viability was assayed after 24 hrs. (B,C) RAW 264.7 (B)
or J774A.1 (C) were treated with zVAD.fmk (100 uM or 50 uM
respectively). Cell viability was assayed after 24 hrs. (D,E) Akt
deficient mouse lung fibroblasts stably expressing Myr-Akt or Myr-
Akt K179M mutant, were stimulated with TNFa and zVAD.fmk
under serum free conditions for 24 hr, followed by cell viability
assay or (D) western blot analysis (E). (F) Mouse lung fibroblasts
expressing one isoform of Akt (Akt1 or Akt2) were treated with
zVAD.fmk and TNFa followed by cell viability assay. In all
graphs, average6SD was plotted.
(TIF)
Figure S10 JNK and c-Jun differentially contribute to
autocrine TNFa production and cell death. (A) Cells were
treated with TNFa or zVAD.fmk with or without SP600125 (SP6)
followed by evaluation of TNFa mRNA levels by qRT-PCR at
9 hrs. (B) L929 cells were treated with TNFa for 9 hrs in the
presence of the JNK inhibitor SP600125 (SP6), Nec-1, JNK inh.
VIII, or Akt inh. VIII and analysed by western blot. (C) Cells were
treated with TNFa with or without JNK inhibitor VIII followed by
evaluation of TNFa mRNA levels by qRT-PCR at 9 hrs. (D) Cells
were treated with zVAD.fmk or TNFa with either SP600125 or
JNK inh VIII followed by viability assay at 24 hr. (E-G) L929 cells
transfected with JNK1 and JNK2 siRNAs for 72 hrs were treated
with zVAD.fmk or TNFa followed by western blot at 9 hr (E),
evaluation of TNFa mRNA levels by qRT-PCR at 9 hrs (F), or
viability assay at 24 hr (G), (H-J) L929 cells transfected with c-jun
siRNAs for 72 hrs were treated with zVAD.fmk or TNFa followed
by western blot at 9 hr (H), evaluation of TNFa mRNA levels by
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